ALK and non-small cell lung carcinoma: That is supported by preclinical data in mouse models with EML4-ALK-positive NSCLC showing a high brain-to-plasma ratio of alectinib [73] and by a phase-I study that detected relevant concentrations of alectinib in the cerebrospinal fluid of patients with brain metastases [74].